XBI
State Street SPDR S&P Biotech ETF
Price Chart
Latest Quote
$154.26
+2.26 (+1.49%)
Current Price
| Previous Close | $152.00 |
| Open | $149.57 |
| Day High | $155.46 |
| Day Low | $149.16 |
| Volume | 11,563,830 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.36% |
| Net Assets | $10.73B |
| Expense Ratio | 0.35% |
| Category | Health |
| Fund Family | State Street Investment Management |
| Net Asset Value | $154.38 |
| Premium/Discount | -0.08% |
| Quarterly Dividend Yield | 0.36% |
| Exchange | PCX |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $155.40 |
| SMA50 | $141.84 |
| SMA200 | $126.46 |
| RSI | 48.17 |
| ATR | 4.2757 |
| Rel Volume | 1.12 |
Performance History
| Week | -3.00% |
| Month | +14.09% |
| Quarter | +13.99% |
| 6 Months | +21.76% |
| YTD | +27.07% |
| Year | +76.46% |
| 3 Years | +83.10% |
| 5 Years | +16.02% |
| 10 Years | +172.12% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $154.26 | 11,569,600 |
| 2026-07-16 | $152.00 | 9,850,600 |
| 2026-07-15 | $156.22 | 5,608,900 |
| 2026-07-14 | $155.45 | 8,187,600 |
| 2026-07-13 | $155.34 | 11,350,500 |
| 2026-07-10 | $159.03 | 12,260,000 |
| 2026-07-09 | $164.28 | 7,532,000 |
| 2026-07-08 | $162.97 | 10,792,500 |
| 2026-07-07 | $163.87 | 9,548,200 |
| 2026-07-06 | $160.81 | 7,470,600 |
| 2026-07-02 | $160.46 | 9,683,200 |
| 2026-07-01 | $156.55 | 7,575,200 |
| 2026-06-30 | $158.25 | 9,017,700 |
| 2026-06-29 | $158.31 | 12,227,900 |
| 2026-06-26 | $155.38 | 11,014,400 |
| 2026-06-25 | $151.59 | 12,268,600 |
| 2026-06-24 | $149.71 | 13,716,000 |
| 2026-06-23 | $147.03 | 10,610,000 |
| 2026-06-22 | $145.86 | 16,738,700 |
| 2026-06-18 | $140.58 | 9,569,900 |
About State Street SPDR S&P Biotech ETF
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
📰 Latest News
How to invest in the weight-loss boom
Yahoo Finance Video • 2026-07-17T16:37:44Z
Has The Bull Market Shifted To Biotech Stocks?
Investor's Business Daily • 2026-07-17T21:16:43Z
Profitable Biotechs Strut Their Stuff As Stock Market Stumbles
Investor's Business Daily • 2026-07-17T17:38:07Z
These Funds Are Suddenly Outperforming Themselves
Trefis • 2026-07-17T12:11:55Z
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
24/7 Wall St. • 2026-07-10T16:04:38Z
Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
Zacks • 2026-07-10T06:37:00Z
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
Motley Fool • 2026-07-09T19:07:25Z
Stocks Look Shaky, But This Sector is Booming (Biotech)
Zacks • 2026-07-09T17:04:00Z
This ETF Is Up Nearly 17% in a Month and Doesn’t Own a Single Share of Nvidia
24/7 Wall St. • 2026-07-06T16:50:46Z
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?
Motley Fool • 2026-07-05T13:35:01Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.